AMG 404

DRUG7 trials

Conditions

Acute Lymphoblastic LeukemiaAdvanced Solid TumorsGlioblastoma or Malignant GliomaKirsten Rat Sarcoma (KRAS) pG12C MutationMetastatic Castration-resistant Prostate CancerSmall Cell Lung Cancer

Phase 1

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

TerminatedNCT03296696

AmgenGlioblastoma or Malignant Glioma

Start: 2018-04-18End: 2021-08-28Updated: 2024-10-29

AMG 404 in Patients With Advanced Solid Tumors

CompletedNCT03853109

AmgenAdvanced Solid Tumors

Start: 2019-03-05End: 2023-11-02Updated: 2025-07-20

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Active, not recruitingNCT04185883

AmgenAdvanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Start: 2019-12-17End: 2027-12-05Updated: 2025-10-22

Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL

CompletedNCT04524455

AmgenAcute Lymphoblastic Leukemia

Start: 2020-10-02End: 2023-01-24Updated: 2024-04-08

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

TerminatedNCT04631601

AmgenMetastatic Castration-resistant Prostate Cancer

Start: 2021-01-15End: 2023-10-23Updated: 2025-10-07

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

CompletedNCT04727554

AmgenAdvanced Solid Tumors

Start: 2021-04-29End: 2023-06-05Updated: 2025-01-06

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

CompletedNCT04885998

AmgenSmall Cell Lung Cancer

Start: 2021-09-27End: 2024-09-11Updated: 2025-09-29

Cancer Research2026-04-03

Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).

Journal of Clinical Oncology2025-05-284 citations

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours

BMJ Open2025-05-01

A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301).

Journal of Clinical Oncology2025-01-272 citations

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

The Oncologist2025-01-012 citations

Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.

Journal of Clinical Oncology2024-06-0115 citations

Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study.

Journal of Clinical Oncology2024-06-011 citations

A phase 1b study of sotorasib combined with panitumumab as second-line treatment of KRAS G12C-mutated colorectal cancer.

Journal of Clinical Oncology2024-01-203 citations

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.

2024-01-0465 citations

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.

Journal of Clinical Oncology2023-06-0118 citations

A phase 1b study of blinatumomab with the anti-programmed cell death (PD)-1 antibody AMG 404 in adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology2022-06-012 citations

A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101).

Journal of Clinical Oncology2022-01-1914 citations

Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2021-05-2013 citations

Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).

Journal of Clinical Oncology2021-05-2010 citations

403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2020-11-011 citations

Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).

Journal of Clinical Oncology2020-05-209 citations

ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)

Neuro-Oncology2019-11-0123 citations

Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.

Journal of Clinical Oncology2019-05-2014 citations

AMG 404

Sponsors

Conditions

Phase 1

Related Papers